Research demonstrating the effectiveness of subcutaneous anifrolumab-fnia as an auto-injector in patients with active systemic lupus erythematosus is the basis of a recent decision in the EU to recommend the treatments approval for this patient population.
Explore the latest lupus nephritis advances in this supplement, covering CAR-T therapy, obinutuzumab data & new diagnostic tools.
Review expert strategies & clinical pearls for managing SLE & lupus nephritis. Get therapeutic updates from the ACR’s 2025 Review Course.
This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
New data: HCQ reduces risk of eGFR decline by 61–73% & slows kidney function loss. Early initiation is critical for renal health in lupus nephritis.
